Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 3 1

Status

Completed 2Recruiting 1Active not recruiting 1

Sponsor Class

INDUSTRY 4OTHER 3NIH 1NETWORK 1

Study Type

Interventional 4

Sponsor

Cancer Type

Thoracic 4Head & Neck 2Tumor-Agnostic 1Other hematologic neoplasm 1Lymphoid 1Gastrointestinal 1

Conditions

Carcinoma, Non-Small-Cell Lung 4Neoplasms 2Lung Neoplasms 1

Interventions

Carboplatin 542Pemetrexed 392pembrolizumab 372Cisplatin 356Paclitaxel 285Docetaxel 240Gemcitabine 168Nivolumab 158Erlotinib Hydrochloride 147Bevacizumab 114atezolizumab 104osimertinib 99durvalumab 92Etoposide 90Gefitinib 68130-nm albumin-bound paclitaxel 65Cetuximab 64Ipilimumab 60Drug Therapy 51Topotecan 48Injections 44Afatinib 41tislelizumab 40Cyclophosphamide 39Albumin-Bound Paclitaxel 37Vinorelbine 36Crizotinib 34cemiplimab 31icotinib 26Radiotherapy 26

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
INDUSTRY × monalizumab × Thoracic × Clear all
NCT05061550 2026-05-22

NeoCOAST-2

AstraZeneca

Phase 2 Recruiting
630 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT05221840 2026-05-18

PACIFIC-9

AstraZeneca

Phase 3 Active not recruiting
1,051 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT03822351 2024-10-08

COAST

MedImmune LLC

Phase 2 Completed
189 enrolled 24 charts
Thoracic

Carcinoma, Non-Small-Cell Lung, Neoplasms

NCT03794544 2022-02-24

Neoadjuvant Durvalumab Alone or in Combination With Novel Agents in Resectable Non-Small Cell Lung Cancer

MedImmune LLC

Phase 2 Completed
84 enrolled 17 charts
Thoracic

Carcinoma, Non-Small-Cell Lung, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡